Esbriet is an oral medicine approved for the treatment of IPF. The mechanism of action of Esbriet is not fully understood, although it is believed to interfere with the production of Transforming Growth Factor (TGF)-beta, a small protein in the body involved in how cells grow and produce scars (fibrosis), and Tumor Necrosis Factor (TNF)-alpha, a small protein that is involved in inflammation. Esbriet has Orphan Drug designation and was approved for use in Europe in 2011 in adults with mild-to-moderate IPF and in the U.S. in patients with IPF in October 2014.
Esbriet is recommended for conditional use for IPF patients in the ATS / ERS / JRS / ALAT treatment guidelines. Pirfenidone has been marketed as Pirespa® since 2008 in Japan and since 2012 in South Korea by Shionogi & Co. Ltd. Under different trade names, pirfenidone is also approved for the treatment of IPF in China, India, Argentina and Mexico.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.